Research

NEW ENGLAND JOURNAL OF MEDICINE                                                                  Nov. 12, 2014

Eric J. Rubin, M.D., Ph.D., and Lindsey R. Baden, M.D.

The Journal has now published detailed clinical information about three patients transferred from West Africa to the United States or Germany in the midst of their illness.

See details of the treatment

http://www.nejm.org/doi/full/10.1056/NEJMe1412744

USA TODAY                                         Nov. 12, 2014
by Liz Sazbo

Doctors Without Borders will begin clinical trials of three experimental Ebola therapies in West Africa in December, the aid group announced Wednesday.

The studies, to be conducted at the group's treatment centers in Guinea and Liberia, will test therapies already used in some Ebola patients in the USA and Europe: the antiviral drugs brincidofovir and favipiravir, as well as blood donations from Ebola survivors.

Brincidofovir, made by Chimerix of North Carolina, was given to cameraman Ashoka Mukpo, Liberian national Thomas Eric Duncan and physician Craig Spencer. Mukpo and Spencer survived. Duncan received the drug just a couple days before he died.

Favipiravir, an anti-flu drug made by Japan's Fujifilm Holding Corp., was given to a French nurse who worked with Doctors Without Borders.

And blood donations from Ebola survivors, which contain antibodies against the virus, have been used since the first Ebola outbreak in 1976.

Read complete story
http://www.usatoday.com/story/news/nation/2014/11/12/ebola-clinical-trial/18919401/

NEW ENGLAND COMPLEX SYSTEMS INSTITUTE                                                                        Oct. 27, 2014
ABSTRACT
By Kia Hall and Yaneer Bar-Yam
The number of cases of Ebola in West Africa has been growing exponentially, and projections assume that this dynamic will continue. However, recent case reports from Liberia indicate a change. The number of new confirmed cases reported by WHO has actually diminished for five weeks in a row.
The WHO report suggests that this may be due to underreporting under conditions of high levels of stress of the number of cases taking place.

Here we report that there appears to be a sound reason for the decreasing number of cases—a change in response strategy that is working. Understanding this dynamic is of critical importance for addressing the outbreak in Sierra Leone and Guinea. In particular the number of cases in Sierra Leone continues to grow exponentially.

Discussions with a WHO response coordinator in Liberia indicates that a change in strategy from individual reporting and contact tracing to community based screening for early detection and population wide behavior change happened in mid September.

Researchers often describe the battle between the Ebola virus and the humans it occasionally infects as a race—one that people win only if their immune systems manage to pull ahead before the virus destroys too many of their internal defenses. What they may not know is that the virus is a cheat.